The Country Caller examines fourth quarter forecasts for Under Armour and Pfizer

Published By: Eunice Gettys on January 30, 2017 10:35 am EST

Under Armour Inc (NYSE:UA) and Pfizer Inc. (NYSE:PFE) are scheduled to report their quarterly financial results during pre-market hours on Tuesday, January 31.  Both companies would report results for the fourth quarter of fiscal year 2016 (4QFY16). Pfizer is expected to outperform Wall Street expectations on bottom line whereas Under Armour is likely to post similar results on the top line this quarter.

Under Armour

The consensus earnings per share (EPS) estimate stands at 25 cents for the quarter, which would represent an increase of 48% year-over-year (YoY). However, if the estimate holds true, the company will face a decline of roughly 13.8% on a quarter-over-quarter (QoQ) basis.

Additionally, Wall Street analysts expect revenue to clock in at $1.41 billion, slightly better than Estimize.com’s prediction of $1.42 billion. Furthermore, analysts’ 4Q estimates are also slightly lower than the company’s previous quarter’s net sales of $1.47 billion. However, the estimate represents an increase of 20.7% YoY.

Pfizer Inc.

Wall Street analysts expect Pfizer’s to post EPS of 50 cents, which would mark a decline of two cents from Estimize.com’s 4Q prediction of 52 cents. If the estimate holds true, the company will experience a decline of 5.66% YoY but a massive increase of 18% QoQ.

Furthermore, revenue is expected to clock in at $13.55 billion, which is slightly below  Estimize.com’s revenue estimate of $13.54 billion. Moreover, if the estimate holds true, revenue will decline 3.21% YoY but increase 4.23% QoQ.